Santa Clara, CA-based Ancora Heart announced on 19 July it raised $80m in equity financing from Sands Capital, Sio Capital and an undisclosed strategic investor to accelerate the CorCinch-HF pivotal trial of the AccuCinch ventricular restoration system for treating patients who have symptomatic heart failure with reduced ejection fraction (HFrEF).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?